FeTPPS
(Synonyms: MESO-四(4-磺酰苯基)卟吩氯化铁) 目录号 : GC43663A peroxynitrite decomposition catalyst
Cas No.:90384-82-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Peroxynitrite is a highly reactive nitrogen species formed from the reaction of nitric oxide (NO) and superoxide.[1] FeTPPS is a ferric porphyrin complex that causes the decomposition of peroxynitrite by catalytic isomerization to produce nitrate both in vitro and in vivo. The conversion of this reactive nitrogen species to nitrate results in cytoprotection (EC50 = 5 µM). [2][3] FeTPPS does not complex with NO and does not alter superoxide directly. It is commonly used to elucidate the roles of peroxynitrite in oxidative stress, cell damage, and intracellular signaling. [4][5][6]
Reference:
[1]. Chen, X., Chen, H., Deng, R., et al. Pros and cons of current approaches for detecting peroxynitrite and their applications. Biomed.J. 37(3), 120-126 (2014).
[2]. Lauzier, B., Sicard, P., Bouchot, O., et al. A peroxynitrite decomposition catalyst: FeTPPS confers cardioprotection during reperfusion after cardioplegic arrest in a working isolated rat heart model. Fundamental Clinical Pharmacology 21, 173-180 (2007).
[3]. Misko, T.P., Highkin, M.K., Veenhuizen, A.W., et al. Characterization of the cytoprotective action of peroxynitrite decomposition catalysts. The Journal of Biological Chemisty 273(25), 15646-15653 (1998).
[4]. Ishrat, T., Kozak, A., Alhusban, A., et al. Role of matrix metalloproteinase activity in the neurovascular protective effects of angiotensin antagonism. Stroke Res.Treat. 2014, 1-9 (2014).
[5]. Li, J., Loukili, N., Rosenblatt-Velin, N., et al. Peroxynitrite is a key mediator of the cardioprotection afforded by ischemic postconditioning in vivo. PLoS One 8(7), 1-8 (2013).
[6]. Kiss, A., Tratsiakovich, Y., Gonon, A.T., et al. The role of arginase and rho kinase in cardioprotection from remote ischemic perconditioning in non-diabetic and diabetic rat in vivo. PLoS One 9(8), 1-8 (2014).
| Cas No. | 90384-82-0 | SDF | |
| 别名 | MESO-四(4-磺酰苯基)卟吩氯化铁 | ||
| 化学名 | Fe(III)5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato chloride | ||
| Canonical SMILES | [Cl-][Fe+3]123[N-]4C5=CC=C4C(C6=CC=C(S([O-])(=O)=O)C=C6)=C(C=C7)[N]1=C7C(C8=CC=C(S([O-])(=O)=O)C=C8)=C(C=C9)[N-]2C9=C(C%10=CC=C(S([O-])(=O)=O)C=C%10)C%11=[N]3C(C=C%11)=C5C%12=CC=C(S([O-])(=O)=O)C=C%12.[H+].[H+].[H+].[H+] | ||
| 分子式 | C44H24ClFeN4O12S4•4H | 分子量 | 1024.3 |
| 溶解度 | 5 mg/ml in water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9763 mL | 4.8814 mL | 9.7628 mL |
| 5 mM | 0.1953 mL | 0.9763 mL | 1.9526 mL |
| 10 mM | 0.0976 mL | 0.4881 mL | 0.9763 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet